Tesla shares take a hit as feud between Trump and Musk reaches a boil
Shares of electric vehicle maker Tesla, which is headed by Elon Musk, slumped Tuesday as the war of words between billionaire and President Donald Trump over the big bill of tax breaks and spending cuts heats up again, with Musk saying he may form a new political party.
Shares of Tesla have already tumbled more than 20% this year as sales of the company's vehicles erode amid a backlash against Musk and his association with the Trump administration. Tesla sales are plummeting in Europe and China as well.
Tesla's stock fell nearly 6% in early trading.
The resumption of hostilities between Trump and Musk, also the CEO of SpaceX, is always bad news for investors in Musk's companies.
'This BFF situation has now turned into a soap opera that remains an overhang on Tesla's stock with investors fearing that the Trump Administration will be more hawkish and show scrutiny around Musk related US government spending related to Tesla/SpaceX and most importantly the autonomous future with the regulatory environment key to the future of Robotaxis and Cybercabs,' wrote Wedbush Securities analyst Dan Ives on Tuesday. 'We would expect the stock to be weak to kick off trading this morning as the Street will show concern that the Trump and Musk once BFF relationship now backfires and turns into a junior high school friendship gone bad into an enemy.'
The most prominent divide in the relationship between Musk and Trump is the president's big bill. Musk ramped up his criticism of the bill over the weekend, arguing the legislation that Republican senators are scrambling to pass would kill jobs and bog down burgeoning industries.
Musk posted on X on Saturday that the bill would be 'political suicide for the Republican Party.'
With the Senate working its way through a tense overnight session that dragged into Tuesday, Musk suggested he will work to get members of Congress who vote for the bill out of their seats next year.
'Every member of Congress who campaigned on reducing government spending and then immediately voted for the biggest debt increase in history should hang their head in shame,' he wrote on X. 'And they will lose their primary next year if it is the last thing I do on this Earth.'
The post was viewed 26 million times on the social media platform.
A few hours later, Musk followed up with a post claiming he will create a new political party if the bill passes.
'If this insane spending bill passes, the America Party will be formed the next day,' he wrote. 'Our country needs an alternative to the Democrat-Republican uniparty so that the people actually have a VOICE.'
Musk's post about the America Party was viewed 32 million times on X.
Trump focused some of his criticisms of Musk on EV mandates and subsidies. In a post on Truth Social early Tuesday, Trump said Musk has known that he's against an EV mandate and that people should not be forced to own electric vehicles.
'Elon may get more subsidy than any human being in history, by far, and without subsidies, Elon would probably have to close up shop and head back home to South Africa,' Trump wrote.
Trump also suggested that the U.S. could cut back on spending by targeting segments of the economy in which Musk plays a significant roll.
'No more Rocket launches, Satellites, or Electric Car Production, and our Country would save a FORTUNE. Perhaps we should have DOGE take a good, hard, look at this? BIG MONEY TO BE SAVED!!!' Trump posted, alluding to the cost-cutting entity that until recently, was headed by Musk.
Several hours later, while standing on the White House lawn before heading to Florida, Trump continued to take shots at Musk and what he believes to be his biggest grievance, the billionaire's displeasure over potentially losing EV subsidies.
'He's very upset. You know, he can lose a lot more than that, I'll tell you right now,' Trump said. 'Elon can lose a lot more than that.'
When asked by a reporter if he was going to deport Musk, Trump warned that the Department of Government Efficiency, or DOGE, could come back to hurt the billionaire.
'We'll have to take a look,' Trump said. 'We might have to put DOGE on Elon. You know what DOGE is? DOGE is the monster that might have to go back and eat Elon. Wouldn't that be terrible? He gets a lot of subsidies.'
Musk responded on X by saying he would refrain from escalating the conflict, but he took another shot at Trump and Republicans anyway.
'What good is Doge saving $160B when this bill increases the debt ceiling by $5T? It makes mockery of the work,' he wrote.
Michelle Chapman, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Winnipeg Free Press
an hour ago
- Winnipeg Free Press
Senate GOP removes tax on solar and wind energy but dismantles climate law passed by Democrats
WASHINGTON (AP) — The sprawling Republican budget bill approved by the Senate Tuesday removes a proposed tax on solar and wind energy projects but quickly phases out tax credits for wind, solar and other renewable energy. The Senate approved the bill 51-50 as President Donald Trump and GOP lawmakers move to dismantle the 2022 climate law passed by Democrats under former President Joe Biden. Vice President JD Vance broke a tie after three Republican senators voted no. The bill now moves to the House for final legislative approval. The excise tax on solar and wind generation projects was added to the Senate bill over the weekend, prompting bipartisan pushback from lawmakers as well as clean energy developers and advocates. The final bill removes the tax but mostly sticks with legislative language released late Friday night and would end incentives for clean energy sooner than a draft version unveiled two weeks ago. Some warn of spike in utility bills Democrats and environmental groups said the GOP plan would crush growth in the wind and solar industry and lead to a spike in Americans' utility bills. The measure jeopardizes hundreds of renewable energy projects slated to boost the nation's electric grid, they said. 'Despite limited improvements, this legislation undermines the very foundation of America's manufacturing comeback and global energy leadership,' said Abigail Ross Hopper, president and CEO of the Solar Energy Industries Association. If the bill becomes law, 'families will face higher electric bills, factories will shut down, Americans will lose their jobs, and our electric grid will grow weaker,' she said. The American Petroleum Institute, the top lobbying group for the oil and gas industry, applauded the bill's passage. 'This historic legislation will help usher in a new era of energy dominance by unlocking opportunities for investment, opening lease sales and expanding access to oil and natural gas development,' said Mike Sommers, the group's president and CEO. While Democrats complained that the bill would make it harder to get renewable energy to the electric grid, Republicans said the measure represents historic savings for taxpayers and supports production of traditional energy sources such as oil, natural gas and coal, as well as nuclear power, increasing reliability. In a compromise approved overnight, the bill allows wind and solar projects that begin construction within a year of the law's enactment to get a full tax credit without a deadline for when the projects are 'placed in service,' or plugged into the grid. Wind and solar projects that begin later must be placed in service by the end of 2027 to get a credit. The bill retains incentives for technologies such as advanced nuclear, geothermal and hydropower through 2032. Changes to the renewable energy language — including removal of the excise tax on wind and solar — were negotiated by a group of Republican senators, including Alaska Sen. Lisa Murkowski and Iowa Sens. Joni Ernst and Chuck Grassley. Iowa is a top producer of wind power, while Murkowski is a longtime supporter of renewable energy as crucial for achieving energy independence, particularly for isolated rural communities in Alaska. Murkowski, who voted in favor of the final bill, called her decision-making process 'agonizing.' 'I had to look on balance, because the people in my state are the ones that I put first,' she told reporters after Tuesday's vote. 'We do not have a perfect bill by any stretch of the imagination.' GOP bill said to be 'massively destructive' Rhode Island Sen. Sheldon Whitehouse, the top Democrat on the Senate Environment and Public Works Committee, called the bill a 'massively destructive piece of legislation' that 'increases costs for everyone by walloping the health care system, making families go hungry and sending utility bills through the roof.' The bill 'saddles our children and grandchildren with trillions and trillions of dollars in debt — all to serve giant corporations, fossil fuel polluters and billionaire Republican megadonors who are already among the richest people on the planet,' Whitehouse said. Wyoming Sen. John Barrasso, a Republican and former chairman of the Senate Energy panel, hailed the bill for rescinding many elements of what he called the Biden administration's 'green new scam,' including electric vehicle tax credits that have allowed car owners to lower the purchase price of EVs by $7,500. The bill also blocks a first-ever fee on excess methane emissions from oil and gas production that industry groups fiercely opposed, increases oil and gas leases on public lands and revives coal leasing in Wyoming and other states. 'Today, the Senate moved President Trump's agenda forward,' said West Virginia Sen. Shelley Moore Capito, a Republican who chairs the Senate environment committee. Wednesdays Columnist Jen Zoratti looks at what's next in arts, life and pop culture. Clean energy advocates were deeply disappointed by the bill, which they argue undoes much of the 2022 climate law approved by Democrats. 'By eliminating a number of clean energy incentives and slashing others, this bill represents a significant step backward for America's energy future,' said Nathaniel Keohane, president of the Center for Climate and Energy Solutions, a nonprofit that seeks to accelerate the global transition to net-zero greenhouse gas emissions. 'Curtailing incentives for electricity generated from wind and solar power is particularly shortsighted' and will raise energy prices for households and businesses and threaten reliability of the electric grid, Keohane said. ___ Associated Press writer Alexa St. John in Detroit contributed to this story.
Globe and Mail
an hour ago
- Globe and Mail
IBN Technologies' Outsourced Accounts Receivable Services Optimize Lease Invoicing for USA Property Firms
"Outsourced Accounts Receivable Services [USA]" Oregon property managers are enhancing lease billing workflows by adopting outsourced accounts receivable services. With rising operational costs and complex tenant agreements, firms are moving to external AR support for streamlined invoicing, escalated term tracking, and accurate prorated charges. Backed by structured receivables frameworks, these services help reduce missed charges and maintain steady rental income. Miami, Florida, 01 July 2025 Property management firms are refining their lease invoicing procedures by transitioning critical receivables functions to specialized partners. In a landscape of commercial tenant agreements, multi-location rentals, and staggered payment schedules, outsourced accounts receivable services are helping companies ensure billing consistency without straining internal teams. Automated billing cycles, variable term management, and prorated charge coordination are now integrated into more responsive receivables frameworks. By embracing third-party oversight, firms gain the ability to optimize AR across seasonal occupancy shifts and long-term contract management. These systems also allow for quick adjustments based on escalations or term renewals—without impacting day-to-day leasing operations. As leasing portfolios grow in complexity, many property firms are anchoring their financial administration to dependable external support models to reinforce tenant trust and maintain predictable income streams. Invoicing Cycles Remain Unstable With inflation pushing up maintenance, insurance, and service fees, property management firms are under pressure to keep tenant billing accurate and on time. Lease escalation terms, shared utility charges, and contract renewals add complexity to monthly invoicing. • Missed charges cause revenue leakage in multi-unit setups • Manual lease terms delay recurring invoices • No real-time visibility into overdue accounts • Occupancy changes are poorly reflected in billing • Teams struggle to manage diverse lease structures As portfolios grow, outsourcing receivables becomes a strategic step. IBN Technologies offers outsourced accounts receivable services designed for property invoicing, helping landlords maintain billing accuracy and optimize AR without overstretching internal teams. Lease Invoicing Moves to Experts Property firms are rethinking monthly billing workflows to stay ahead of rising operational costs and tenant diversification. With escalating lease terms and custom charges, outsourcing accounts receivable is becoming the standard for property finance teams. ✅ Lease invoicing standardized across multi-unit and commercial properties ✅ Escalation clauses tracked accurately in recurring AR workflows ✅ Prorated charges and shared expenses billed seamlessly ✅ Tenant balances monitored through structured receivables tracking ✅ Move-in/move-out billing adjustments handled by external teams ✅ Collections oversight done professionally across occupancy types ✅ Portfolio-wide invoice reporting aligned with owner expectations From large metro markets to mixed-use zones across the USA, firms are adopting outsourced accounts receivable services in Oregon delivered by leaders like IBN Technologies. These services ensure accuracy, reduce missed charges, and streamline tenant billing—making outsourcing a sound financial step. Oregon Property Managers Simplify Lease Billing Property firms in Illinois are embracing outsourced receivables to keep pace with changing occupancy terms and fee structures. Streamlined invoicing systems are helping firms bill tenants on time and with fewer adjustments. ✔️ Recurring lease billing accuracy improves by 29%, reducing delays ✔️ Missed charges fall 24%, improving net income consistency ✔️ Admin teams reclaim 13 hours weekly for lease management ✔️ Move-in/out charges better integrated into billing cycles ✔️ Detailed statements support tenant and investor communication Oregon-based property groups are improving billing precision and oversight. IBN Technologies delivers dedicated outsourced accounts receivable services tailored to the needs of commercial and residential portfolios. Property Firms Upgrade Invoicing Models Property management companies are moving away from traditional lease tracking as they expand portfolios and tenant categories. Billing delays, unbilled charges, and unclear payment terms often emerge in manual systems, which can impact occupancy rates and monthly cash flows. By turning to outsourced accounts receivable services, real estate firms gain access to accurate invoicing, consistent follow-ups, and full transparency across their rental income streams. Whether managing commercial spaces or residential units, this support ensures rent, service charges, and renewals are billed and collected without gaps. In today's property environment, financial structure must match operational scale. A reliable AR process helps managers handle complex lease terms, shared utilities, and custom agreements with consistency. As outsourcing eliminates manual reconciliation and delayed notices, firms experience smoother cash cycles and fewer disputes with tenants. This evolution in billing allows property teams to focus on occupancy strategies, service enhancements, and expansion goals—while maintaining the financial discipline needed to thrive in competitive real estate markets. Related Service: About IBN Technologies IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.
Globe and Mail
an hour ago
- Globe and Mail
Non-Hodgkin Lymphoma Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Non-Hodgkin Lymphoma Pipeline Insight, 2025 ' report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Non-Hodgkin Lymphoma Treatment Landscape. Click here to read more @ Non-Hodgkin Lymphoma Pipeline Outlook Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report In June 2025, AstraZeneca announced a study is designed to evaluate the safety, tolerability, PK, and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies. In June 2025, Genmab conducted a study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. In June 2025, Artiva Biotherapeutics Inc. organized clinical trial will enroll patients with relapsed/refractory non-Hodgkin lymphoma of B-cell origin and is conducted in two phases. The primary objectives of Phase 1 are as follows: 1) to evaluate the safety of AB-101 given alone or in combination with rituximab (including the DLBCL specific cohort) or in combination with bendamustine and rituximab; 2) to evaluate the potential clinical activity of AB-101 when given in combination with rituximab or in combination with bendamustine and rituximab (combination cohorts only); and 3) to identify the recommended Phase 2 dose (RP2D). The primary objective of Phase 2 is to determine whether AB-101 in combination with rituximab or in combination with bendamustine and rituximab has anti-cancer activity in patients. DelveInsight's Non-Hodgkin Lymphoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Non-Hodgkin Lymphoma treatment. The leading Non-Hodgkin Lymphoma Companies such as Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Promising Non-Hodgkin Lymphoma Pipeline Therapies such as Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Discover groundbreaking developments in Non-Hodgkin Lymphoma Therapies! Gain in-depth knowledge of key Non-Hodgkin Lymphoma clinical trials, emerging drugs, and market opportunities @ Non-Hodgkin Lymphoma Clinical Trials Assessment Non-Hodgkin Lymphoma Emerging Drugs Profile Golcadomide: Bristol Myers Squibb Golcadomide is a novel cereblon E3 ligase modulator (CELMoD) being investigated for the treatment of aggressive B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL). In combination with R-CHOP chemotherapy, it has shown promising antitumor activity in high-risk DLBCL patients, with a high overall response rate (ORR) and complete metabolic response (CMR). Currently, the drug is in Phase III stage of its clinical trial for the treatment of Non-Hodgkin Lymphoma. MEN 1703: Ryvu Therapeutics MEN1703 (SEL24) is a clinical-stage program discovered and developed by Ryvu Therapeutics and licensed to the Menarini Group. MEN1703 is a first-in-class, dual PIM/FLT3 kinase inhibitor with a unique activity profile. By design, this profile may provide responses to treatment that are more durable than current options and address a disease that has progressed following FLT3 inhibition. Preclinical data suggests therapeutic potential in both hematological malignancies and in solid tumors. Ryvu has granted the Menarini Group an exclusive worldwide license to further research, develop, manufacture and commercialize MEN1703 (SEL24). Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. LP-168: Guangzhou Lupeng Pharmaceutical LP-168 is a third-generation, orally active, irreversible EGFR tyrosine kinase inhibitor (TKI) developed by Guangzhou Lupeng Pharmaceutical for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, including T790M resistance mutations. It is designed to target mutant EGFR while sparing wild-type EGFR, potentially reducing side effects. LP-168 has shown promising preclinical activity and is currently in clinical trials. The company is exploring its use in both first-line and resistant EGFR-mutant NSCLC settings. Currently the drug is in Phase II stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. DR-0201: Dren Bio DR-0201 is an investigational drug developed by D.R. Pharmatech, designed as a novel anti-cancer agent targeting HER2-expressing tumors, particularly in gastric and breast cancers. It is a HER2-targeting antibody-drug conjugate (ADC) that combines a monoclonal antibody with a cytotoxic payload to selectively kill cancer cells while minimizing damage to healthy tissue. DR-0201 aims to overcome resistance seen with existing HER2 therapies. The product is currently undergoing preclinical or early-phase clinical evaluation. Currently the drug is in Phase I stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. ETR-7072 is an investigational small-molecule drug developed by EntreChem, designed to target cancer by modulating transcriptional programs involved in tumor growth and survival. It is part of EntreChem's novel class of natural product-inspired compounds with multi-targeted activity, potentially affecting epigenetic regulators and oncogenic pathways. ETR-7072 shows promise in preclinical models for treating aggressive and resistant cancers. The compound is currently in early-stage development, with ongoing studies to assess its safety and efficacy. Currently the drug is in Preclinical stage of its clinical development for the treatment of B-cell Non-Hodgkin Lymphoma. The Non-Hodgkin Lymphoma Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Non-Hodgkin Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Hodgkin Lymphoma Treatment. Non-Hodgkin Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Non-Hodgkin Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Hodgkin Lymphoma market Stay informed about the Non-Hodgkin Lymphoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Non-Hodgkin Lymphoma Unmet Needs Non-Hodgkin Lymphoma Companies Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Transform your understanding of the Non-Hodgkin Lymphoma Pipeline! See the latest progress in drug development and clinical research @ Non-Hodgkin Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Non-Hodgkin Lymphoma Pipeline Report Coverage- Global Non-Hodgkin Lymphoma Companies- Bristol Mayer Squibb, Beijing Mabworks Biotech, CARGO Therapeutics, Guangzhou Lupeng Pharmaceutical, Ryvu Therapeutics, Dren Bio, ImmunityBio, Merck, EntreChem, Bantam Pharmaceutical, Vironexis Biotherapeutics, Excyte Biopharma, Owkin, AstraZeneca, ST Phi Therapeutics, NovImmune SA and others. Non-Hodgkin Lymphoma Pipeline Therapies- Bendamustine hydrochloride injection, Glofitamab, Atezolizumab, Obinutuzumab, Lenalidomide, Velcade, Temsirolimus, PF-3512676 and others. Non-Hodgkin Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Non-Hodgkin Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Stay Ahead in Research-Access the Full Non-Hodgkin Lymphoma Pipeline Analysis Today! @ Non-Hodgkin Lymphoma Drugs and Companies Table of Contents Introduction Executive Summary Non-Hodgkin Lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Non-Hodgkin Lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Golcadomide: Bristol Myers Squibb Mid Stage Products (Phase II) MEN 1703: Ryvu Therapeutics Early Stage Products (Phase I) DR-0201: Dren Bio Preclinical and Discovery Stage Products ETR-7072: EntreChem Inactive Products Non-Hodgkin Lymphoma Key Companies Non-Hodgkin Lymphoma Key Products Non-Hodgkin Lymphoma- Unmet Needs Non-Hodgkin Lymphoma- Market Drivers and Barriers Non-Hodgkin Lymphoma- Future Perspectives and Conclusion Non-Hodgkin Lymphoma Analyst Views Non-Hodgkin Lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
